Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

The Whole of Disney Stock Is Greater than the Sum of Its Parts

By Chris Markoch, InvestorPlace Contributor

Although producing an unexpected earnings beat would be an amazing achievement for Disney, the most important factor for DIS stock is its myriad businesses and powerful brand name.

Don’t Like the MSFT Stock Valuation? Wait a Day.

By Chris Markoch, InvestorPlace Contributor

Although Microsoft stock may look overvalued, you have to consider the bigger picture. When you do, you’ll see that MSFT offers comprehensive coverage to relevant tech subsegments.

3 Blue Chip Stocks for Investors Who are Hungry for Growth

By Chris Markoch, InvestorPlace Contributor

Blue chip stocks are known for rock-solid performance that sometimes comes at the expense of growth. Here are three that are providing both.

NIO Stock Has a Math Problem

By Chris Markoch, InvestorPlace Contributor

Nio stock is down over 90% for 2019, and the company is facing problems in obtaining financing and in getting operating costs under control.

Will Aurora Stock Rise After Medical CBD Win?

By Chris Markoch, InvestorPlace Contributor

With the honeymoon phase fading for the legal cannabis market, embattled Aurora Cannabis stock still enjoys the massive tailwind of medical marijuana.

Load More